Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Summerway Capital PLC on Monday said it completed the acquisition of medical-cannabis firm Vertigrow Technology Ltd, or Celadon Pharmaceuticals.
Summerway added that a name change to Celadon Pharmaceuticals PLC will become effective on Tuesday.
It acquired Vertigrow for £80 million. It funded the deal through an issue of 48.5 million shares at 165 pence each.
Celadon's focus will be the research, cultivation, manufacturing and supply of cannabinoid-based medicines, its predecessor company said. Before that, Summerway Capital was a company investing in household and consumer goods sectors.
Summerway noted that at full capacity, its facility could supply up to 50,000 patients and also has the potential to generate £90 million in annual revenue.
Shares in Summerway were 6.3% lower at 148.00 pence each in London on Monday afternoon.
Copyright 2022 Alliance News Limited. All Rights Reserved.